m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01809)
Name
ST-1646
Synonyms
CHEMBL392303
    Click to Show/Hide
Status
Investigative
Structure
Formula
C21H33N7O6
InChI
1S/C21H33N7O6/c22-21(23)24-8-2-5-12-18(32)15-7-6-11-3-1-4-13(20(34)28(11)15)26-14(9-17(30)31)19(33)25-10-16(29)27-12/h11-15,26H,1-10H2,(H,25,33)(H,27,29)(H,30,31)(H4,22,23,24)/t11-,12-,13-,14+,15+/m0/s1
InChIKey
MYSBVCKSODARFZ-BTFPBAQTSA-N
PubChem CID
44439175
TTD Drug ID
D0R9SJ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
ITGB3 messenger RNA (ITGB3 mRNA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for ST-1646. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ST-1646 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). [1], [2]
References
Ref 1 Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3. Cancer Res. 2019 Sep 15;79(18):4612-4626. doi: 10.1158/0008-5472.CAN-19-0799. Epub 2019 Jul 22.
Ref 2 Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106. doi: 10.1021/jm049165z.